What is Entera Bio Ltd's earnings per share (EPS)?

Entera Bio Ltd (ENTX) reported diluted earnings per share of $0.25 for fiscal year 2025. This represents a 0.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Entera Bio Ltd Financials

ENTX

Source SEC Filings (10-K/10-Q) Updated Mar 27, 2026 Currency USD FYE March

This page shows Entera Bio Ltd (ENTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 33/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Entera Bio Ltd has an operating margin of -27450.0%, meaning the company retains $-27450 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -5295.6% the prior year.

Growth

Entera Bio Ltd's revenue declined 76.8% year-over-year, from $181K to $42K. This contraction results in a growth score of 0/100.

Leverage

Entera Bio Ltd carries a low D/E ratio of 0.22, meaning only $0.22 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 98/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 6.94, Entera Bio Ltd holds $6.94 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

While Entera Bio Ltd generated -$7.4M in operating cash flow, capex of $107K consumed most of it, leaving -$7.5M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Entera Bio Ltd generates a -87.3% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -118.1% the prior year.

Piotroski F-Score Weak

3/9

Entera Bio Ltd passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.64x

For every $1 of reported earnings, Entera Bio Ltd generates $0.64 in operating cash flow (-$7.4M OCF vs -$11.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$42K

YoY-76.8%

5Y CAGR-35.1%

Entera Bio Ltd generated $42K in revenue in fiscal year 2025. This represents a decrease of 76.8% from the prior year.

EBITDA

-$11.5M

YoY-20.5%

Entera Bio Ltd's EBITDA was -$11.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 20.5% from the prior year.

Net Income

-$11.4M

YoY-19.9%

Entera Bio Ltd reported -$11.4M in net income in fiscal year 2025. This represents a decrease of 19.9% from the prior year.

EPS (Diluted)

$0.25

YoY+0.0%

Entera Bio Ltd earned $0.25 per diluted share (EPS) in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$7.5M

YoY-9.6%

Entera Bio Ltd generated -$7.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 9.6% from the prior year.

Cash & Debt

$7.1M

YoY-17.9%

5Y CAGR-3.7%

Entera Bio Ltd held $7.1M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

47M

YoY+20.0%

5Y CAGR+14.5%

Entera Bio Ltd had 47M shares outstanding in fiscal year 2025. This represents an increase of 20.0% from the prior year.

Margins & Returns

Gross Margin

21.4%

YoY+16.5pp

5Y CAGR+3.6pp

Entera Bio Ltd's gross margin was 21.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 16.5 percentage points from the prior year.

Operating Margin

-27450.0%

YoY-22154.4pp

5Y CAGR-24390.3pp

Entera Bio Ltd's operating margin was -27450.0% in fiscal year 2025, reflecting core business profitability. This is down 22154.4 percentage points from the prior year.

Net Margin

-27235.7%

YoY-21964.4pp

5Y CAGR-24162.8pp

Entera Bio Ltd's net profit margin was -27235.7% in fiscal year 2025, showing the share of revenue converted to profit. This is down 21964.4 percentage points from the prior year.

Return on Equity

-87.3%

YoY+30.8pp

5Y CAGR+62.0pp

Entera Bio Ltd's ROE was -87.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 30.8 percentage points from the prior year.

Capital Allocation

R&D Spending

$6.0M

YoY+33.5%

5Y CAGR-1.2%

Entera Bio Ltd invested $6.0M in research and development in fiscal year 2025. This represents an increase of 33.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$107K

YoY+3466.7%

5Y CAGR+15.1%

Entera Bio Ltd invested $107K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 3466.7% from the prior year.

ENTX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$42K-76.8%	$181K	$0-100.0%	$134K-76.5%	$571K+56.4%	$365K
Cost of Revenue	$42K-75.6%	$172K	$0-100.0%	$101K-72.9%	$373K+24.3%	$300K
Gross Profit	$9K0.0%	$9K	$0-100.0%	$33K-83.3%	$198K+204.6%	$65K
R&D Expenses	$6.0M+33.5%	$4.5M-0.2%	$4.5M-22.9%	$5.8M-13.6%	$6.8M+6.1%	$6.4M
SG&A Expenses	$398K-92.2%	$5.1M+15.0%	$4.4M-38.9%	$7.3M+27.5%	$5.7M+17.3%	$4.9M
Operating Income	-$11.5M-20.3%	-$9.6M-7.8%	-$8.9M+31.7%	-$13.0M-6.5%	-$12.2M-9.4%	-$11.2M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$14K0.0%	$14K-51.7%	$29K-78.8%	$137K+332.2%	-$59K-395.0%	$20K
Net Income	-$11.4M-19.9%	-$9.5M-7.3%	-$8.9M+32.0%	-$13.1M-7.3%	-$12.2M-8.7%	-$11.2M
EPS (Diluted)	$0.250.0%	$0.25-19.4%	$0.31-31.1%	$0.45-4.3%	$0.47	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$0	$0-100.0%	$42K	N/A	$42K-26.3%	$57K	$0	N/A
Cost of Revenue	$0	$0-100.0%	$42K	N/A	$42K-12.5%	$48K	$0	N/A
Gross Profit	$0	$0	$0	N/A	$0-100.0%	$9K	$0	N/A
R&D Expenses	$1.6M+8.1%	$1.5M+35.4%	$1.1M	N/A	$1.5M+36.0%	$1.1M+47.8%	$735K	N/A
SG&A Expenses	$122K+18.4%	$103K-92.8%	$1.4M	N/A	$62K-53.7%	$134K-89.9%	$1.3M	N/A
Operating Income	-$3.3M-22.0%	-$2.7M-4.1%	-$2.6M	N/A	-$3.0M-39.5%	-$2.2M-5.0%	-$2.1M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	$0	N/A	N/A	N/A
Net Income	-$3.2M-20.5%	-$2.7M-3.5%	-$2.6M	N/A	-$3.0M-40.8%	-$2.1M-6.3%	-$2.0M	N/A
EPS (Diluted)	$0.07+16.7%	$0.060.0%	$0.06	N/A	$0.08+33.3%	$0.06+20.0%	$0.05	N/A

ENTX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$16.0M+70.3%	$9.4M-20.2%	$11.8M-10.4%	$13.1M-49.5%	$26.0M+167.3%	$9.7M
Current Assets	$15.3M+70.5%	$9.0M-20.3%	$11.3M-12.4%	$12.8M-49.3%	$25.3M+178.1%	$9.1M
Cash & Equivalents	$7.1M-17.9%	$8.7M-21.4%	$11.0M-10.5%	$12.3M-50.6%	$24.9M+189.7%	$8.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$126K0.0%	$126K	$0-100.0%	$246K+34.4%	$183K-28.2%	$255K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.9M+120.8%	$1.3M-5.0%	$1.4M+0.4%	$1.4M-59.9%	$3.4M+54.7%	$2.2M
Current Liabilities	$2.2M+87.3%	$1.2M+7.8%	$1.1M-18.6%	$1.3M-57.6%	$3.2M+71.7%	$1.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$13.1M+62.1%	$8.1M-22.2%	$10.4M-11.6%	$11.8M-47.9%	$22.6M+200.5%	$7.5M
Retained Earnings	-$125.4M-10.0%	-$113.9M-9.1%	-$104.4M-9.3%	-$95.5M-15.9%	-$82.4M-17.4%	-$70.2M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$17.4M-11.5%	$19.7M-8.9%	$21.6M+130.0%	$9.4M+21.3%	$7.7M-22.9%	$10.0M-2.0%	$10.2M-13.0%	$11.8M
Current Assets	$17.0M-11.9%	$19.3M-9.0%	$21.2M+136.5%	$9.0M+22.2%	$7.3M-23.5%	$9.6M-1.6%	$9.8M-13.4%	$11.3M
Cash & Equivalents	$8.6M-21.0%	$10.9M-13.6%	$12.6M+45.2%	$8.7M+25.2%	$6.9M-23.6%	$9.1M-1.4%	$9.2M-16.6%	$11.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$0	$0-100.0%	$126K0.0%	$126K+200.0%	$42K-26.3%	$57K	N/A	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.2M-9.9%	$2.4M+8.6%	$2.2M+69.5%	$1.3M+1.6%	$1.3M-14.2%	$1.5M+9.2%	$1.4M-0.2%	$1.4M
Current Liabilities	$1.6M-14.8%	$1.8M+13.6%	$1.6M+38.0%	$1.2M+5.9%	$1.1M-14.1%	$1.3M+15.4%	$1.1M+2.7%	$1.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$15.2M-11.7%	$17.3M-11.0%	$19.4M+139.8%	$8.1M+25.2%	$6.5M-24.4%	$8.5M-3.7%	$8.9M-14.7%	$10.4M
Retained Earnings	-$122.3M-2.7%	-$119.2M-2.3%	-$116.5M-2.3%	-$113.9M-2.1%	-$111.6M-2.8%	-$108.5M-2.0%	-$106.4M-1.9%	-$104.4M

ENTX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$7.4M-8.1%	-$6.8M+6.7%	-$7.3M+41.5%	-$12.5M-37.9%	-$9.1M+14.2%	-$10.6M
Capital Expenditures	$107K+3466.7%	$3K-82.4%	$17K-63.8%	$47K+176.5%	$17K-67.9%	$53K
Free Cash Flow	-$7.5M-9.6%	-$6.8M+6.9%	-$7.3M+41.6%	-$12.5M-38.2%	-$9.1M+14.4%	-$10.6M
Investing Cash Flow	-$107K-3466.7%	-$3K+82.4%	-$17K+83.3%	-$102K-500.0%	-$17K+67.9%	-$53K
Financing Cash Flow	$13.7M+206.3%	$4.5M-25.8%	$6.0M+46330.8%	$13K-99.9%	$25.4M+526.5%	$4.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$2.5M-53.4%	-$1.6M-16.2%	-$1.4M+4.3%	-$1.5M+31.9%	-$2.2M-61.3%	-$1.3M+28.3%	-$1.9M+28.8%	-$2.6M
Capital Expenditures	$43K+48.3%	$29K+262.5%	$8K+166.7%	$3K	$0	$0	$0-100.0%	$5K
Free Cash Flow	-$2.5M-53.3%	-$1.7M-17.6%	-$1.4M+3.9%	-$1.5M+31.8%	-$2.2M-61.3%	-$1.3M+28.3%	-$1.9M+29.0%	-$2.6M
Investing Cash Flow	-$43K-48.3%	-$29K-262.5%	-$8K-166.7%	-$3K	$0	$0	$0+100.0%	-$5K
Financing Cash Flow	$250K+590.2%	-$51K-100.4%	$13.3M+314.6%	$3.2M+24646.2%	$13K-98.9%	$1.2M+3953.3%	$30K-99.5%	$6.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ENTX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	21.4%+16.5pp	5.0%	N/A	24.6%-10.1pp	34.7%+16.9pp	17.8%
Operating Margin	-27450.0%-22154.4pp	-5295.6%	N/A	-9714.2%-7574.6pp	-2139.6%+920.1pp	-3059.7%
Net Margin	-27235.7%-21964.4pp	-5271.3%	N/A	-9754.5%-7620.1pp	-2134.3%+938.6pp	-3072.9%
Return on Equity	-87.3%+30.8pp	-118.1%-32.5pp	-85.6%+25.6pp	-111.2%-57.2pp	-54.0%+95.3pp	-149.3%
Return on Assets	-71.5%+30.1pp	-101.6%-26.1pp	-75.5%+24.0pp	-99.6%-52.7pp	-46.9%+68.5pp	-115.4%
Current Ratio	6.94-0.7	7.63-2.7	10.32+0.7	9.58+1.6	8.01+3.1	4.95
Debt-to-Equity	0.22+0.1	0.16+0.0	0.13+0.0	0.12-0.0	0.15-0.1	0.29
FCF Margin	-17802.4%-14033.9pp	-3768.5%	N/A	-9362.7%-7772.5pp	-1590.2%+1316.7pp	-2906.8%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	0.0%	N/A	0.0%-15.8pp	15.8%	N/A	N/A
Operating Margin	N/A	N/A	-6102.4%	N/A	-7192.9%-3394.6pp	-3798.3%	N/A	N/A
Net Margin	N/A	N/A	-6111.9%	N/A	-7192.9%-3429.7pp	-3763.2%	N/A	N/A
Return on Equity	-21.0%-5.6pp	-15.4%-2.1pp	-13.3%	N/A	-46.8%-21.7pp	-25.1%-2.4pp	-22.8%	N/A
Return on Assets	-18.4%-4.9pp	-13.5%-1.6pp	-11.9%	N/A	-39.0%-17.6pp	-21.4%-1.7pp	-19.7%	N/A
Current Ratio	10.83+0.4	10.47-2.6	13.07+5.4	7.63+1.0	6.61-0.8	7.42-1.3	8.70-1.6	10.32
Debt-to-Equity	0.140.0	0.14+0.0	0.11-0.0	0.16-0.0	0.20+0.0	0.18+0.0	0.16+0.0	0.13
FCF Margin	N/A	N/A	-3361.9%	N/A	-5128.6%-2786.5pp	-2342.1%	N/A	N/A

Similar Companies

Ovid Therapeutics Inc OVID

$326.2M

$412.0M

$71.3M

$37.0M

$5.7M

Frequently Asked Questions

What is Entera Bio Ltd's annual revenue?

Entera Bio Ltd (ENTX) reported $42K in total revenue for fiscal year 2025. This represents a -76.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Entera Bio Ltd's revenue growing?

Entera Bio Ltd (ENTX) revenue declined by 76.8% year-over-year, from $181K to $42K in fiscal year 2025.

Is Entera Bio Ltd profitable?

No, Entera Bio Ltd (ENTX) reported a net income of -$11.4M in fiscal year 2025, with a net profit margin of -27235.7%.

What is Entera Bio Ltd's EBITDA?

Entera Bio Ltd (ENTX) had EBITDA of -$11.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Entera Bio Ltd's gross margin?

Entera Bio Ltd (ENTX) had a gross margin of 21.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Entera Bio Ltd's operating margin?

Entera Bio Ltd (ENTX) had an operating margin of -27450.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Entera Bio Ltd's net profit margin?

Entera Bio Ltd (ENTX) had a net profit margin of -27235.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Entera Bio Ltd's return on equity (ROE)?

Entera Bio Ltd (ENTX) has a return on equity of -87.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Entera Bio Ltd's free cash flow?

Entera Bio Ltd (ENTX) generated -$7.5M in free cash flow during fiscal year 2025. This represents a -9.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Entera Bio Ltd's operating cash flow?

Entera Bio Ltd (ENTX) generated -$7.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Entera Bio Ltd's total assets?

Entera Bio Ltd (ENTX) had $16.0M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Entera Bio Ltd's capital expenditures?

Entera Bio Ltd (ENTX) invested $107K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Entera Bio Ltd spend on research and development?

Entera Bio Ltd (ENTX) invested $6.0M in research and development during fiscal year 2025.

How many shares does Entera Bio Ltd have outstanding?

Entera Bio Ltd (ENTX) had 47M shares outstanding as of fiscal year 2025.

What is Entera Bio Ltd's current ratio?

Entera Bio Ltd (ENTX) had a current ratio of 6.94 as of fiscal year 2025, which is generally considered healthy.

What is Entera Bio Ltd's debt-to-equity ratio?

Entera Bio Ltd (ENTX) had a debt-to-equity ratio of 0.22 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Entera Bio Ltd's return on assets (ROA)?

Entera Bio Ltd (ENTX) had a return on assets of -71.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Entera Bio Ltd's cash runway?

Based on fiscal year 2025 data, Entera Bio Ltd (ENTX) had $7.1M in cash against an annual operating cash burn of $7.4M. This gives an estimated cash runway of approximately 12 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Entera Bio Ltd's Piotroski F-Score?

Entera Bio Ltd (ENTX) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Entera Bio Ltd's earnings high quality?

Entera Bio Ltd (ENTX) has an earnings quality ratio of 0.64x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Entera Bio Ltd?

Entera Bio Ltd (ENTX) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.